Login to Your Account

Anti-TNFs, Rituxan, Orencia ... ?

While RA Bids Line Runway, Poll Finds Unhappy Patients

By Randall Osborne

Monday, October 29, 2007
The phrase "rheumatoid arthritis" almost right away calls to mind Genentech Inc.'s Rituxan (rituximab, which targets the CD20 antigen, for RA and non-Hodgkin's lymphoma). (BioWorld Financial Watch)

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription